Pharma C Investments - Restoration, Issue of Equity and Proposed Board
22/12/2023 12:44
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231222:nRSV8260Xa&default-theme=true
RNS Number : 8260X Pharma C Investments PLC 22 December 2023
22 December 2023
Pharma C Investments PLC
("Pharma C" or the "Company")
Restoration to Trading, Issue of Equity, Proposed Board Changes and PDMR
Pharma C (AQSE: PCIL) is pleased to announce that, following the publication
of the Interim results, trading in the Ordinary Shares of the Company will
resume at 8am on Wednesday, 27 December 2023.
Issue of Equity
As per the Notice of General Meeting dated 24 November 2023, the Company had
conditionally raised £281,000 by way of the Subscription of 2,810,000,000
subscription shares ("Subscription Shares") at the price of £0.0001 ("Issue
Price"). The Subscription was conditional upon the passing of the resolutions
at the General Meeting and admission of the Subscription Shares to trading on
AQSE. Following the resolutions being passed at the General Meeting held on 11
December 2023 and the restoration to trading on AQSE, a total of 2,810,000,000
Subscription Shares will be issued. In addition, the Company has agreed to
settle further outstanding debt by issuing 25,000,000 Subscription Shares at
the Issue Price. The Subscription Shares will represent a total of 91.31% of
the enlarged share capital.
Application will be made for the Subscription Shares, which will rank pari
passu with the existing Ordinary Shares in issue, to be admitted to trading on
the AQSE Growth Market ("Admission"). Dealings are expected to commence on or
around 2 January 2024.
Total Voting Rights
Following Admission, the Company's total issued and voting share capital will
consist of 3,104,857,144 Ordinary Shares. The Company does not hold any
ordinary shares in treasury.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules
Board Changes
The Company is also today announcing the following Board appointments which
will be made once First Sentinel Corporate Finance has conducted the necessary
checks as required by the AQSE Rules. A further announcement will be made upon
the appointments being made:
- Peter Wall joins as Executive Chairman;
- Philipp Kallerhoff and Sarah Gow join as Non-Executive Directors;
- Gavin Sathianathan steps down from the board as Investment Strategy
Director once the above appointments become effective;
- Jeremy Woodgate remains on the Board as Independent Non-Executive
Director.
Peter Wall is an active leader in the technology sector, best known for his
tenure as CEO and Chairman of Argo Blockchain, a company he guided to a
successful NASDAQ listing in 2021. Under his leadership, Argo raised over $200
million in capital, solidifying its status as a key player in the blockchain
industry. Peter was the driving force behind Argo's growth, starting with
assembling its initial team and establishing the first facility in Gatineau,
Quebec, to orchestrating expansive operations and adopting innovative
technologies that enhanced efficiency and minimized environmental impact.
In addition to his achievements at Argo, Peter served as Chairman of
LSE-listed Cellular Goods. His ability to navigate complex technological
landscapes has also led to significant contributions across various other
industries, including co-working, journalism, and communications.
Philipp Kallerhoff is an accomplished leader in the fields of technology and
finance. As the founder of Protos Management, Philipp has been at the
forefront of digital asset investment, demonstrating his deep understanding of
the blockchain industry. His tenure as Director at Harcourt/Vontobel Asset
Management AG in Zurich emphasized his proficiency in applying machine
learning to market dynamics. Philipp's entrepreneurial journey includes
co-founding Jumiya Inc., which transformed financial data analysis through big
data analytics.
An alumnus of Singularity University with a Doctorate in Computational
Neuroscience and multiple degrees from TU Berlin, Philipp skillfully blends
academic rigor with entrepreneurial zeal. His educational background in
engineering, management, psychology, and physics underlines his
multidisciplinary approach to problem-solving and innovation.
Sarah Gow brings over 19 years of banking industry expertise, with significant
roles at Citigroup Asset Management, where she served as Director of Global
Operations in New York and Head of Operations in London. Sarah's strategic
vision and operational leadership were also evident during her tenure at HSBC
Global Asset Management as a Project Manager. As a founding partner of
UK-based TrinityCapM Ltd, she demonstrated her entrepreneurial acumen in asset
management. Notably, Sarah contributed her governance and oversight skills to
the board of Argo Blockchain, playing a key role during its milestone NASDAQ
listing in 2021.
Information for the purpose of Rule 4.9 of the AQSE Growth Market Access
Rulebook for the new directors will be provided once the board appointments
have been made.
The Directors of Pharma C take responsibility for this announcement.
For further information please visit www.pharmacinvestments.com
(http://www.pharmacinvestments.com)
Pharma C Investments
Gavin Sathianathan Via First Sentinel
First Sentinel Corporate Finance
Brian Stockbridge, Corporate Adviser +44 20 3855 5551
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Jeremy Woodgate
2. Reason for the Notification
a) Position/status Independent Non-Executive Director
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Pharma C Investments PLC
b) LEI 213800CBZ6E6WRDGV387
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares
Identification Code GB00BJDPYD55
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s) Price(s) Volume(s)
£0.0001 per Ordinary Share 25,000,000 Ordinary Shares
d) Aggregated information:
· Aggregated volume 25,000,000 Ordinary Shares
· Price £2,500
e) Date of the transaction 27 December 2023
f) Place of the Transaction Aquis Stock Exchange
d)
Aggregated information:
· Aggregated volume
· Price
25,000,000 Ordinary Shares
£2,500
e)
Date of the transaction
27 December 2023
f)
Place of the Transaction
Aquis Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NEXDZMZZZZDGFZM